Ferroptosis is a regulated form of cell death triggered by iron-dependent accumulation of lipid peroxides, leading to plasma membrane rupture. Unlike apoptosis or necrosis, it involves the collapse of lipid homeostasis due to glutathione peroxidase 4 (GPX4) inactivation and excessive reactive oxygen species in the presence of redox-active iron.
Discovered in 2012, ferroptosis is distinct from other cell death pathways because it hinges on iron metabolism and oxidative damage to polyunsaturated fatty acids (PUFAs) in membranes. It is not caused by caspase activation or mitochondrial permeability transition, which define apoptosis and necrosis. Instead, it results from the failure of the glutathione-GPX4 axis, a central antioxidant system.
Research from the laboratory of Dr. Brent Stockwell at Columbia University identified ferroptosis through screening compounds that selectively killed cancer cells lacking certain antioxidant defenses. This work revealed that erastin and RSL3 induce ferroptosis by inhibiting system Xc⁻ or GPX4, respectively. These findings established ferroptosis as a targetable process in disease contexts.
Ferroptosis begins when intracellular iron levels rise and catalyze Fenton reactions, generating hydroxyl radicals from hydrogen peroxide. These radicals attack PUFAs in phospholipid membranes, initiating a chain reaction of lipid peroxidation. Without functional GPX4, the cell cannot reduce these peroxides, leading to irreversible membrane damage.
The process is tightly linked to cellular iron metabolism. Iron is stored in ferritin, but under stress, ferritin can degrade via ferritinophagy-a selective autophagy pathway involving NCOA4. This releases free Fe²⁺, which fuels ROS production. Elevated labile iron pools increase sensitivity to ferroptosis inducers.
A key regulatory node is the cystine/glutamate antiporter (system Xc⁻). This transporter imports cystine, which is converted to cysteine-the rate-limiting precursor for glutathione synthesis. Inhibiting system Xc⁻ with drugs like erastin depletes glutathione, disabling GPX4 and allowing lipid peroxides to accumulate. This mechanism explains why many cancer cells are vulnerable to ferroptosis when their antioxidant systems are compromised.
Several proteins and enzymes govern ferroptosis susceptibility. GPX4 is the primary defense enzyme-it uses glutathione to reduce lipid hydroperoxides to harmless alcohols. Loss of GPX4 activity, either genetically or pharmacologically, induces ferroptosis. In mice, conditional knockout of Gpx4 in neurons causes rapid neurodegeneration, demonstrating its essential role in tissue survival.
ACSL4 (acyl-CoA synthetase long-chain family member 4) promotes ferroptosis by incorporating PUFAs into phosphatidylethanolamine (PE) lipids. Cells expressing high ACSL4 are more sensitive to lipid peroxidation. Studies show that ACSL4 expression correlates with ferroptosis induction in cancer lines, especially those with high PUFA content in membranes.
Other regulators include SLC7A11 (subunit of system Xc⁻), FSP1 (ferredoxin reductase 1), and CoQ10. FSP1 acts independently of GPX4 by reducing ubiquinone to ubiquinol, which scavenges lipid radicals. This pathway provides a parallel antioxidant shield, highlighting the redundancy in ferroptosis control.
| Molecule | Role in Ferroptosis | Effect of Loss/Inhibition |
|---|---|---|
| GPX4 | Reduces lipid peroxides using glutathione | Induces ferroptosis |
| System Xc⁻ (SLC7A11) | Imports cystine for glutathione synthesis | Depletes glutathione; triggers ferroptosis |
| ACSL4 | Enriches membranes with PUFAs | Increases sensitivity to ferroptosis |
| FSP1 | Generates reduced CoQ10 to scavenge radicals | Protects against ferroptosis |
Ferroptosis plays a role in multiple diseases. In cancer, some tumors are highly susceptible due to elevated iron uptake and low GPX4 expression. For example, glioblastoma and renal cell carcinoma often have mutations that impair antioxidant capacity, making them vulnerable to ferroptosis-inducing therapies.
In neurodegenerative disorders, ferroptosis contributes to neuronal loss. Post-mortem brain samples from patients with Alzheimer's and Parkinson's show increased lipid peroxidation markers and iron deposits in affected regions. In animal models, administering ferroptosis inhibitors like liproxstatin-1 slows cognitive decline and reduces neuron death.
Acute kidney injury (AKI) also involves ferroptosis. A 2020 study published in *Nature Medicine* showed that ischemia-reperfusion injury in mouse kidneys led to GPX4 degradation and lipid peroxidation. Administering ferrostatin-1 improved survival and function in these animals, suggesting therapeutic potential.
Ferroptosis is not synonymous with iron overload or general oxidative stress. While both involve iron and ROS, ferroptosis is a specific, genetically regulated pathway. Iron accumulation alone does not cause ferroptosis unless combined with defective antioxidant defenses and PUFA-rich membranes.
Another misconception is that ferroptosis only affects diseased cells. In reality, it can occur in healthy tissues under extreme conditions. For example, during severe hypoxia or in response to certain toxins, even normal cells may undergo ferroptosis if their antioxidant systems are overwhelmed.
Ferroptosis is not a passive consequence of cell damage. It is actively regulated by multiple signaling nodes. The discovery of FSP1 as a GPX4-independent protector shows that cells have evolved layered defenses against this form of death.
Consider a patient with a triple-negative breast cancer tumor. These cancers lack estrogen, progesterone, and HER2 receptors, limiting treatment options. Research shows they often overexpress SLC7A11 and depend on system Xc⁻ for survival. When treated with erastin, cystine import stops, glutathione drops, GPX4 becomes inactive, and lipid peroxides build up.
Within 6 hours of exposure, electron microscopy reveals swollen mitochondria with condensed membranes-hallmarks of ferroptosis. By 24 hours, cell death occurs via membrane rupture, not apoptosis. In mouse xenograft models, combining erastin with standard chemotherapy reduces tumor volume by 70% compared to controls.
This example illustrates how targeting ferroptosis offers a strategy to kill therapy-resistant cancers. Clinical trials are now testing ferroptosis inducers in combination with immune checkpoint inhibitors, aiming to improve antitumor immunity.
Ferroptosis is a distinct, iron-dependent form of regulated cell death driven by uncontrolled lipid peroxidation. It arises when antioxidant systems like GPX4 fail under conditions of high iron and PUFA availability. Its role spans cancer, neurodegeneration, and organ injury, making it a promising target for drug development. Understanding what is ferroptosis enables precise interventions in disease contexts where traditional cell death pathways do not apply.